We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Regulatory News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Jul 2005 10:14

VASTox plc04 July 2005 SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Name of company Vastox plc 2. Name of shareholder having a major interest Lansdowne Partners Limited Partnership 3. Please state whether notification indicates that it is in respect of holdingof the shareholder named in 2 above or in respect of a non-beneficial interestor in the case of an individual holder if it is a holding of that person'sspouse or children under the age of 18 On behalf of funds that it manages 4. Name of the registered holder(s) and, if more than one holder, the number ofshares held by each of them Not notified 5. Number of shares / amount of stock acquired Not notified 6. Percentage of issued class Not notified 7. Number of shares / amount of stock disposed N/A 8. Percentage of issued class N/A 9. Class of security Ordinary Shares 10. Date of transaction 1 July 2005 11. Date company informed 4 July 2005 12. Total holding following this notification 2,120,000 Ordinary Shares 13. Total percentage holding of issued class following this notification 6.77% 14. Any additional information N/a 15. Name of contact and telephone number for queries Darren Millington01235 443 903 16. Name and signature of authorised company official responsible for makingthis notification Darren Millington Date of notification 4 July 2005 The FSA does not give any express or implied warranty as to the accuracy of thisdocument or material and does not accept any liability for error or omission.The FSA is not liable for any damages (including, without limitation, damagesfor loss of business or loss of profits) arising in contract, tort or otherwisefrom the use of or inability to use this document, or any material contained init, or from any action or decision taken as a result of using this document orany such material. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Apr 201912:00 pmGNWSummit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
2nd Apr 201912:00 pmGNWSummit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29th Mar 20195:45 pmGNWAward of Share Options
29th Mar 201911:15 amGNWFiling of Annual Report on Form 20-F
27th Mar 201911:00 amGNWFinal Results
25th Mar 201911:00 amGNWNotice of Results
18th Mar 201911:00 amGNWSummit Therapeutics to Present at Upcoming Conferences
14th Mar 201911:00 amGNWSummit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25th Feb 201912:00 pmGNWSummit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13th Feb 201912:00 pmGNWSummit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
8th Feb 201912:00 pmGNWSummit Therapeutics to Present at the BIO CEO & Investor Conference
15th Jan 20195:45 pmGNWHolding(s) in Company
14th Jan 201912:00 pmGNWAward of Restricted Stock Units
10th Jan 20194:15 pmGNWHolding(s) in Company
10th Jan 201911:30 amGNWHolding(s) in Company
10th Jan 20197:00 amGNWCompletion of $25 million Subscription
9th Jan 20194:45 pmGNWHolding(s) in Company
8th Jan 20197:00 amGNWUpdate on Admission
4th Jan 201912:30 pmGNWResult of General Meeting
2nd Jan 20199:40 amGNWHolding(s) in Company
18th Dec 201812:15 pmGNWHolding(s) in Company
17th Dec 20187:05 amGNWProposed Subscription to Raise $25m and Notice of General Meeting
17th Dec 20187:00 amGNWSummit Therapeutics Announces Departure of Chief Financial Officer
11th Dec 201812:00 pmGNW3rd Quarter Results
6th Dec 201812:00 pmGNWSummit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30th Nov 20181:30 pmGNWHolding(s) in Company
12th Nov 201812:00 pmGNWSummit Highlights Importance of Innovation in Fight Against Antibiotic Resistance During Antibiotics Awareness Week
12th Nov 20187:00 amGNWAppointment of Joint Broker
7th Nov 201812:00 pmGNWSummit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
1st Nov 20184:34 pmGNWHolding(s) in Company
1st Nov 201811:00 amGNWSummit Recognises C. difficile Awareness Month
24th Oct 20184:15 pmGNWDirector/PDMR Shareholding
22nd Oct 20187:00 amGNWAward of Share Options
20th Sep 201812:00 pmGNWSummit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
27th Dec 20177:00 amRNSAcquisition of Discuva Ltd
10th May 20122:04 pmRNSGrant of Options
30th Dec 200911:07 amRNSResult of GM
30th Dec 20097:00 amRNSResult of Placing and Open Offer
11th Dec 200912:53 pmRNSPlacing and Open Offer and Appointment of NOMAD
11th Dec 200912:40 pmRNSWellcome Trust Grant
31st Jan 20087:00 amRNSTrading Statement
16th Jan 20087:01 amRNSStart of Ph II clinical trial
6th Dec 20077:00 amRNSChange of Adviser
5th Nov 200711:18 amRNSDirector/PDMR Shareholding
30th Oct 20077:02 amRNSRe Agreement
30th Oct 20077:01 amRNSInterim Results
25th Oct 20074:07 pmRNSHolding in Company
23rd Oct 20077:02 amRNSClinical Update
12th Oct 20079:00 amRNSNotice of Results
2nd Oct 20077:01 amRNSResearch Donation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.